UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Seminars in oncology, 2015-08, Vol.42 (4), p.539-548

2015

Volltextzugriff (PDF)

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy : The Underlying Mechanisms and Clinical Management

Scientifica (Cairo), 2013-01, Vol.2013 (2013), p.1-19

2013

Volltextzugriff (PDF)

Immunotherapy of cancer in 2012

CA: a cancer journal for clinicians, 2012-09, Vol.62 (5), p.309-335

2012

Volltextzugriff (PDF)

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

International journal of radiation oncology, biology, physics, 2016-06, Vol.95 (2), p.632-646

2016

Volltextzugriff (PDF)

Update on adjuvant therapy in late-stage resected melanoma

Clinical advances in hematology & oncology, 2021-12, Vol.19 (12), p.753

Tarhini, Ahmad A

2021

Volltextzugriff (PDF)

IFN-α in the treatment of melanoma

The Journal of immunology (1950), 2012-10, Vol.189 (8), p.3789-3793

2012

Volltextzugriff (PDF)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Journal of clinical oncology, 2023-01, Vol.41 (2), p.186-197

2023

Volltextzugriff (PDF)

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Journal of clinical oncology, 2020-02, Vol.38 (6), p.567-575

2020

Volltextzugriff (PDF)

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

Journal of clinical oncology, 2012-01, Vol.30 (3), p.322-328

2012

Volltextzugriff (PDF)

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

Journal of clinical oncology, 2019-12, Vol.37 (35), p.3350-3358

2019

Volltextzugriff (PDF)

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PloS one, 2021-01, Vol.16 (1), p.e0245287-e0245287

2021

Volltextzugriff (PDF)

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

Cancer research (Chicago, Ill.), 2014-02, Vol.74 (4), p.1045-1055

2014

Volltextzugriff (PDF)

Immune Checkpoint Blockade and Interferon-α in Melanoma

Seminars in oncology, 2015-06, Vol.42 (3), p.436-447

2015

Volltextzugriff (PDF)

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Journal of clinical oncology, 2018-12, Vol.36 (35), p.JCO1800632-3458

2018

Volltextzugriff (PDF)

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

Journal of the American College of Surgeons, 2020-11, Vol.231 (5), p.554-556

2020

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4066-4076

2015

Volltextzugriff (PDF)

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Oncoimmunology, 2019-11, Vol.8 (11), p.e1652538

2019

Volltextzugriff (PDF)

Next Generation of Immunotherapy for Melanoma

Journal of clinical oncology, 2008-07, Vol.26 (20), p.3445-3455

2008

Volltextzugriff (PDF)

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Melanoma research, 2022-02, Vol.32 (1), p.35-44

2022

Volltextzugriff (PDF)

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Obesity surgery, 2022-04, Vol.32 (4), p.970-978

2022

Volltextzugriff (PDF)

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Molecular cancer therapeutics, 2024-08, Vol.23 (8), p.1139-1143

2024

Volltextzugriff (PDF)

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma

Cancers, 2023-06, Vol.15 (12), p.3180

2023

Volltextzugriff (PDF)

Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages

Immunity (Cambridge, Mass.), 2024-05, Vol.57 (5), p.1124-1140.e9

2024

Volltextzugriff (PDF)

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3773-3776

2012

Volltextzugriff (PDF)

1 – 25 von 243

Suche als RSS-Feed

Aktive Filter

KollektionNature

Zeitschrift / SerieClinical Cancer Research

ThemaMelanoma

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(224)
Mit Volltextzugriff
(208)

Publikationsform

Sprache

Englisch
(243)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy : The Underlying Mechanisms and Clinical Management

Immunotherapy of cancer in 2012

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)

Update on adjuvant therapy in late-stage resected melanoma

IFN-α in the treatment of melanoma

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma

CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines

Immune Checkpoint Blockade and Interferon-α in Melanoma

Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma

Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma

The impact of CTLA-4 blockade and interferon-α on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients

Next Generation of Immunotherapy for Melanoma

Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

One-Anastomosis Gastric Bypass Revision for Gastroesophageal Reflux Disease: Long Versus Short Biliopancreatic Limb Roux-en-Y Gastric Bypass

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma

Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages

How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?

Aktive Filter

Suchergebnisse filtern